| |
With a 60+ year legacy of excellence in bioscience manufacturing, Puerto Rico is a hub for groundbreaking discoveries in the region & beyond. Local talent, tax benefits & the island's decades of expertise fuel companies like CytoImmune & OcyonBio. Learn more. 
|
|
Today’s Big NewsJan 29, 2024 |
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
| By Ben Adams,Nick Paul Taylor Every year, we tap Evaluate Vantage’s annual preview report to assess the biggest potential new drugs of the year ahead. Typically, major pharmaceutical and biotechnology companies are featured, each presenting potential blockbuster launches. In 2024, however, things are set to play out a little differently. |
|
|
|
By Annalee Armstrong Sarepta Therapeutics' next Duchenne muscular dystrophy med seems to be doing the job of spurring dystrophin expression. But does any of the data for SRP-5051 matter given the recent approval of the biotech’s gene therapy for the same condition, Elevidys? |
By Andrea Park Though both Philips and the FDA have agreed to the terms of the decree, it’s still in the process of being finalized, after which it’ll be sent off for court approval. |
By Fraiser Kansteiner Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act alert. The site is the former headquarters of Global Blood Therapeutics. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
By James Waldron With last week seeing back-to-back oversized biotech IPOs to kick off the new year, it’s no surprise that Fractyl Health is now kicking its own offering plans up a gear. |
By Gabrielle Masson Shanghai-based biotech Laekna's oral cancer drug afuresertib has failed to significantly improve progression-free survival for patients with ovarian cancer in a phase 2 trial. |
By Angus Liu Merck’s unique approval for Keytruda as a postsurgerical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives. This comes just as the drug’s rival, Bristol Myers Squibb’s Odpivo, chalked up another trial failure. |
By Andrea Park The Innovative Science and Technology Approaches for New Drugs pilot was designed to create a new pathway to FDA review for novel tools that may not fit into currently existing routes of evaluation, but that could potentially improve the development of new drugs. |
By Fraiser Kansteiner With the unusual threat of a Senate subpoena hanging over their heads, the CEOs of Johnson & Johnson and Merck & Co. have agreed to join their counterpart at Bristol Myers Squibb in testifying before the Senate Committee on Health, Education, Labor and Pensions (HELP). |
By Conor Hale The electronics giant signed a three-year contract through its Boston Imaging unit. |
By Nick Paul Taylor Pharma watchers know Sanofi has changed how it presents itself to the world. Under CEO Paul Hudson, Sanofi has pitched itself as humble, authentic, a bit unconventional—and changed its branding to match. But people in the wider world? Well, reaching them poses a different challenge. Sanofi’s attempt to rise to that challenge is supported by a once-in-a-lifetime opportunity: a Summer Olympics in France. |
By Nick Paul Taylor Roche has waved goodbye to one of its KRAS prospects, terminating an alliance with Hookipa Pharma 15 months after betting $25 million on its novel approach to the oncogene. Shortly after receiving the news, Hookipa decided to lay off 30% of its employees and focus on a slimmed-down list of candidates. |
By Angus Liu Bristol Myers Squibb is offering a detailed look at pivotal data showing an under-the-skin version of its PD-1 inhibitor Opdivo works as well as the original intravenous formulation in kidney cancer. |
By Conor Hale The Cleveland Clinic portfolio company said the proceeds will help it meet rising demand for its IsoPSA test and expand into other types of cancer. |
Fierce podcasts Don’t miss an episode |
| While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
